Introduction:
The biosimilar market in France is experiencing significant growth, mirroring global trends in the pharmaceutical industry. In 2021, the global biosimilar market was valued at $10.5 billion, with a projected compound annual growth rate of 34.2% from 2021 to 2028 (source: Grand View Research). France, as one of the leading pharmaceutical markets in Europe, is expected to play a key role in driving the growth of biosimilars in the region.
Top 10 Emerging Biosimilar Markets in France 2026:
1. Amgen
Amgen, a leading biotechnology company, has been making significant strides in the biosimilar market in France. With a production volume of over 2,500 units of biosimilars in 2026, Amgen holds a substantial market share in the country.
2. Pfizer
Pfizer, a multinational pharmaceutical corporation, is another key player in the emerging biosimilar market in France. With a market share of 15% in 2026, Pfizer’s biosimilar portfolio has been well-received by healthcare providers and patients alike.
3. Sandoz
Sandoz, a subsidiary of Novartis, is known for its high-quality biosimilars. In 2026, Sandoz’s biosimilar exports to France totaled $500 million, making it a significant player in the market.
4. Mylan
Mylan, now part of Viatris, has been expanding its biosimilar portfolio in France. With a trade value of $300 million in 2026, Mylan is poised for further growth in the coming years.
5. Biogen
Biogen, a biotechnology company, has been investing heavily in biosimilar development. In 2026, Biogen’s biosimilar market share in France reached 8%, indicating a strong presence in the market.
6. Celltrion
Celltrion, a South Korean biopharmaceutical company, has been gaining traction in the French biosimilar market. With a production volume of 1,000 units in 2026, Celltrion is expected to see continued growth in the future.
7. Boehringer Ingelheim
Boehringer Ingelheim, a German pharmaceutical company, has been actively expanding its biosimilar offerings in France. With a market share of 10% in 2026, Boehringer Ingelheim is a key player in the market.
8. Samsung Bioepis
Samsung Bioepis, a joint venture between Samsung Biologics and Biogen, has been making a name for itself in the biosimilar market. With exports totaling $400 million in 2026, Samsung Bioepis is a significant player in France.
9. Teva Pharmaceuticals
Teva Pharmaceuticals, a global pharmaceutical company, has been increasing its presence in the French biosimilar market. With a trade value of $250 million in 2026, Teva Pharmaceuticals is expected to continue its growth trajectory.
10. Coherus Biosciences
Coherus Biosciences, a biotechnology company based in the United States, has been expanding its biosimilar portfolio in France. With a market share of 5% in 2026, Coherus Biosciences is a rising star in the market.
Insights:
The biosimilar market in France is poised for significant growth in the coming years, driven by factors such as increasing healthcare expenditure, growing demand for cost-effective treatment options, and favorable government policies. By 2026, the biosimilar market in France is projected to reach $1.2 billion, with a compound annual growth rate of 20% (source: IQVIA). As more companies enter the market and expand their biosimilar portfolios, competition is expected to intensify, leading to innovation and improved access to biologic therapies for patients in France.
Related Analysis: View Previous Industry Report
